These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 10146960)

  • 1. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wynne HA; Campbell M
    Pharmacoeconomics; 1993 Feb; 3(2):107-23. PubMed ID: 10146960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
    Al MJ; Maniadakis N; Grijseels EW; Janssen M
    Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.
    Barradell LB; Whittington R; Benfield P
    Pharmacoeconomics; 1993 Feb; 3(2):140-71. PubMed ID: 10146962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care.
    Fendrick AM
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis.
    Jobanputra P; Nuki G
    Curr Opin Rheumatol; 1994 Jul; 6(4):433-9. PubMed ID: 8068516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Haglund U; Svarvar P
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epidemiology of nonsteroidal anti-inflammatory drugs.
    Tenenbaum J
    Can J Gastroenterol; 1999 Mar; 13(2):119-22. PubMed ID: 10203429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ; Figgitt DP
    Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The appropriate use of NSAIDs in arthritic conditions.
    Moskowitz RW
    Am J Orthop (Belle Mead NJ); 1996 Sep; 25(9 Suppl):4-6. PubMed ID: 8886211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?
    Bloor K; Maynard A
    Pharmacoeconomics; 1996 Jun; 9(6):484-96. PubMed ID: 10160476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
    Yun HR; Bae SC
    Rheumatol Int; 2005 Jan; 25(1):9-14. PubMed ID: 13680139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
    Katz JN; Smith SR; Collins JE; Solomon DH; Jordan JM; Hunter DJ; Suter LG; Yelin E; Paltiel AD; Losina E
    Osteoarthritis Cartilage; 2016 Mar; 24(3):409-18. PubMed ID: 26525846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
    Svarvar P; Aly A
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():43-50. PubMed ID: 11276802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.
    Greene JM; Winickoff RN
    Arch Intern Med; 1992 Oct; 152(10):1995-2002. PubMed ID: 1417372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children's hospitals.
    Slaughter JL; Reagan PB; Bapat RV; Newman TB; Klebanoff MA
    Eur J Pediatr; 2016 Jun; 175(6):775-83. PubMed ID: 26879388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.